Galectin-3 participates in cardiovascular remodeling associated with obesity

Hypertension

Volumn 66, Issue 5, 2015, Pages 961-969

  Martínez Martínez, Ernesto ^a   López Ándres, Natalia ^a,b   Jurado López, Raquel ^c,d   Rousseau, Elodie ^b   Bartolomé, Mará Visitación ^e   Fernández Celis, Amaya ^a   Rossignol, Patrick ^b   Islas, Fabian ^f   Antequera, Alfonso ^g   Prieto, Santiago ^g   Luaces, María ^f   Cachofeiro, Victoria ^c,d  

^a Atención Primaria Y Promoción de La Salud   (Spain)

^b UNIVERSITÉ DE LORRAINE   (France)

^c SCHOOL OF MEDICINE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

Author keywords

fibrosis; galectin 3; inflammation; obesity; vascular stiffness

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; GALECTIN 3; GELATINASE A; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; PECTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FIBROSIS; DIASTOLIC DYSFUNCTION; DIET INDUCED OBESITY; FEMALE; GENE EXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIPID DIET; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; UPREGULATION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR SYSTEM; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; FIBROSIS; HEART MUSCLE; HEART VENTRICLE; HEART VENTRICLE REMODELING; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; INFLAMMATION; MIDDLE AGED; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; STATISTICAL MODEL; WISTAR RAT;

ADULT; ANIMALS; CARDIOVASCULAR SYSTEM; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GALECTIN 3; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIUM; OBESITY; PECTINS; RATS; RATS, WISTAR; REGRESSION ANALYSIS; VENTRICULAR REMODELING;

EID: 84943408497     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06032     Document Type: Article

References (38)

1. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA., Impact of obesity on cardiovascular disease. Med Clin North Am 2011 95 919 937. doi: 10.1016/j.mcna.2011.06.005
2. Abel ED, Litwin SE, Sweeney G., Cardiac remodeling in obesity. Physiol Rev 2008 88 389 419. doi: 10.1152/physrev.00017.2007
3. Martínez-Martínez E, Miana M, Jurado-López R, Bartolomé MV, Souza Neto FV, Salaices M, López-Andrés N, Cachofeiro V., The potential role of leptin in the vascular remodeling associated with obesity. Int J Obes (Lond) 2014 38 1565 1572. doi: 10.1038/ijo.2014.37
4. Martínez-Martínez E, Jurado-López R, Valero-Muñoz M, Bartolomé MV, Ballesteros S, Luaces M, Briones AM, López-Andrés N, Miana M, Cachofeiro V., Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. J Hypertens 2014 32 1104 14; discussion 1114. doi: 10.1097/HJH.0000000000000149
5. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, De Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N., Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013 33 67 75. doi: 10.1161/ATVBAHA.112.300569
6. Sharma UC, Pokharel S, Van Brakel TJ, Van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM., Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004 110 3121 3128. doi: 10.1161/01.CIR.0000147181.65298.4D.
7. De Boer RA, Voors AA, Muntendam P, Van Gilst WH, Van Veldhuisen DJ., Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail 2009 11 811 817. doi: 10.1093/eurjhf/hfp097
8. Papaspyridonos M, McNeill E, De Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR., Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008 28 433 440. doi: 10.1161/ATVBAHA.107.159160
9. Van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM., Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006 48 1217 1224. doi: 10.1016/j.jacc.2006.03.061
10. Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P., Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012 14 74 81. doi: 10.1093/eurjhf/hfr151
11. Gunning AP, Bongaerts RJ, Morris VJ., Recognition of galactan components of pectin by galectin-3. FASEB J 2009 23 415 424. doi: 10.1096/fj.08-106617
12. De Boer RA, Van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, Van Gilst WH, Hillege HL, Bakker SJ, Van der Harst P., The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012 272 55 64. doi: 10.1111/j.1365-2796.2011.02476.x.
13. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schäffler A, Aslanidis C, Schölmerich J, Buechler C., Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010 95 1404 1411. doi: 10.1210/jc.2009-1619
14. Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N., The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 2015 3 59 67. doi: 10.1016/j.jchf.2014.08.002
15. Glinsky VV, Raz A., Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res 2009 344 1788 1791. doi: 10.1016/j.carres.2008.08.038
16. Maeso R, Rodrigo E, Muñoz-García R, Navarro-Cid J, Ruilope LM, Cachofeiro V, Lahera V., Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. J Hypertens 1998 16 665 672
17. Martínez-Martínez E, Miana M, Jurado-López R, Rousseau E, Rossignol P, Zannad F, Cachofeiro V, López-Andrés N., A role for soluble ST2 in vascular remodeling associated with obesity in rats. PLoS One 2013 8 e79176. doi: 10.1371/journal.pone.0079176
18. Stolen CM, Adourian A, Meyer TE, Stein KM, Solomon SD., Plasma galectin-3 and heart failure outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Card Fail 2014 20 793 799. doi: 10.1016/j.cardfail.2014.07.018
19. López B, González A, Querejeta R, Zubillaga E, Larman M, Díez J., Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur J Heart Fail 2015 17 385 392. doi: 10.1002/ejhf.246
20. Cavalera M, Wang J, Frangogiannis NG., Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res 2014 164 323 335. doi: 10.1016/j.trsl.2014.05.001
21. Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, Marwick TH., Fibrosis and cardiac function in obesity: A randomised controlled trial of aldosterone blockade. Heart 2013 99 320 326. doi: 10.1136/heartjnl-2012-303329
22. Eschalier R, Rossignol P, Kearney-Schwartz A, Adamopoulos C, Karatzidou K, Fay R, Mandry D, Marie PY, Zannad F., Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension 2014 63 740 746. doi: 10.1161/HYPERTENSIONAHA.113.02419
23. Luaces M, Cachofeiro V, García-Muñoz-Najar A, Medina M, González N, Cancer E, Rodríguez-Robles A, Cánovas G, Antequera-Pérez A., Anatomical and functional alterations of the heart in morbid obesity. Changes after bariatric surgery. Rev Esp Cardiol (Engl Ed) 2012 65 14 21. doi: 10.1016/j.recesp.2011.06.018
24. Utsunomiya H, Yamamoto H, Kunita E, Hidaka T, Kihara Y., Insulin resistance and subclinical abnormalities of global and regional left ventricular function in patients with aortic valve sclerosis. Cardiovasc Diabetol 2014 13 86. doi: 10.1186/1475-2840-13-86
25. Antonini-Canterin F, Mateescu AD, Vriz O, La Carrubba S, Di Bello V, Carerj S, Zito C, Sparacino L, Marzano B, Usurelu C, Ticulescu R, Ginghinə C, Nicolosi GL, Popescu BA., Cardiac structure and function and insulin resistance in morbidly obese patients: does superobesity play an additional role? Cardiology 2014 127 144 151. doi: 10.1159/000355260
26. Bender SB, DeMarco VG, Padilla J, Jenkins NT, Habibi J, Garro M, Pulakat L, Aroor AR, Jaffe IZ, Sowers JR., Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension 2015 65 1082 1088. doi: 10.1161/HYPERTENSIONAHA.114.04912
27. Pieruzzi F, Antolini L, Salerno FR, Giussani M, Brambilla P, Galbiati S, Mastriani S, Rebora P, Stella A, Valsecchi MG, Genovesi S., The role of blood pressure, body weight and fat distribution on left ventricular mass, diastolic function and cardiac geometry in children. J Hypertens 2015 33 1182 1192. doi: 10.1097/HJH.0000000000000552
28. Rashid MA, Qureshi BA, Ahmed N, Sherwani MA., Impact of body mass index on left ventricular mass. J Ayub Med Coll Abbottabad 2014 26 167 169
29. Zhang K, Huang F, Chen J, Cai Q, Wang T, Zou R, Zuo Z, Wang J, Huang H., Independent influence of overweight and obesity on the regression of left ventricular hypertrophy in hypertensive patients: A meta-analysis. Medicine (Baltimore) 2014 93 e130. doi: 10.1097/MD.0000000000000130
30. Murdolo G, Angeli F, Reboldi G, Di Giacomo L, Aita A, Bartolini C, Vedecchia P., Left ventricular hypertrophy and obesity: only a matter of fat? High Blood Press Cardiovasc Prev 2015 22 29 41. doi: 10.1007/s40292-014-0068-x.
31. Hashmi S, Al-Salam S., Galectin-3 is expressed in the myocardium very early post-myocardial infarction. Cardiovasc Pathol 2015 24 213 223. doi: 10.1016/j.carpath.2014.12.001
32. Martín R, Cordova C, San Román JA, Gutierrez B, Cachofeiro V, Nieto ML., Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease. J Mol Cell Cardiol 2014 72 250 262. doi: 10.1016/j.yjmcc.2014.04.002
33. Lok SI, Nous FM, Van Kuik J, Van der Weide P, Winkens B, Kemperman H, Huisman A, Lahpor JR, De Weger RA, De Jonge N., Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support. Eur J Cardiothorac Surg 2015 48 407 415. doi: 10.1093/ejcts/ezu539
34. Vergaro G, Del Franco A, Giannoni A, Prontera C, Ripoli A, Barison A, Masci PG, Aquaro GD, Cohen Solal A, Padeletti L, Passino C, Emdin M., Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Int J Cardiol 2015 184 96 100. doi: 10.1016/j.ijcard.2015.02.008
35. De Boer RA, Van der Velde AR, Mueller C, Van Veldhuisen DJ, Anker SD, Peacock WF, Adams KF, Maisel A., Galectin-3: A modifiable risk factor in heart failure. Cardiovasc Drugs Ther 2014 28 237 246. doi: 10.1007/s10557-014-6520-2
36. Pineda MA, Cuervo H, Fresno M, Soto M, Bonay P., Lack of galectin-3 prevents cardiac fibrosis and effective immune responses in a murine model of trypanosoma cruzi infection [published online ahead of print March 24, 2015]. J Infect Dis. doi: 10.1093/infdis/jiv185. http://jid.oxfordjournals.org/content/early/2015/05/04/infdis.jiv185.abstract. Accessed August 26, 2015
37. Weir RA, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, McInnes IB, Squire IB, Ng LL, Dargie HJ, McMurray JJ., Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail 2013 6 492 498. doi: 10.1161/CIRCHEARTFAILURE.112.000146
38. Beiras-Fernandez A, Weis F, Rothkopf J, Kaczmarek I, Ledderose C, Dick A, Keller T, Beiras A, Kreth S., Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. Ann Transplant 2013 18 643 650. doi: 10.12659/AOT.889396